Compare Gilead Sciences, Inc. (GILD) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Thomson Reuters Corp — how do they compare? Gilead Sciences, Inc. trades at $133.19 (market cap $163.51B), while Thomson Reuters Corp trades at $97.1 (market cap $41.16B). The key difference: Gilead Sciences, Inc. is far larger — about 4× Thomson Reuters Corp's market cap, and Thomson Reuters Corp pays the higher dividend (2.74%). Which is the better fit depends on your goals.
| GILD | TRI | |
|---|---|---|
Market Cap | $163.51B | $41.16B |
Sector | Health | Industrials |
52-Week High | $155.80 | $211.14 |
52-Week Low | $108.22 | $76.55 |
Enterprise Value | $178.05B | $43.12B |
Dividend Yield | 2.49% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Thomson Reuters (TRI) trades at $97.56, up 6.34% today, showing strong momentum amid positive technical signals. The company maintains robust fundamentals with $7.48B revenue, 19.93% net margin, and consistent earnings beats in recent quarters. Recent developments include a joint venture with KKR for the global print business and continued AI integration across legal and professional services. Technical indicators show bullish momentum with support at $91 and resistance at $93.
TRI presents a compelling investment case with strong analyst support (52% buy ratings) and a $129.96 consensus price target offering 33% upside. Key risks include execution challenges in AI adoption and potential margin pressure from restructuring. The company's solid cash flow generation and strategic partnerships position it well for sustained growth, though investors should monitor Q2 2026 earnings due August 5th for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
